A committee of the European Medicines Agency has recommended approving Uplizna (inebilizumab-cdon) for adults with neuromyelitis optica spectrum disorder (NMOSD) who test positive for aquaporin-4 water channel autoantibodies (AQP4-IgG). This recommendation from the Committee for Medicinal Products for Human Use, known as CHMP, will now be reviewed by…
AQP4 autoantibodies
Recent Posts
- NMOSD treatment approved in China blocks relapses, study finds
- Probing my spirituality in life with chronic illness and hardship
- New study identifies genetic variants tied to AQP4-positive NMOSD
- Uplizna cuts NMOSD relapse risk, even after using immunosuppressants
- Pain, fatigue in NMOSD not captured by standard physical disability scores